EGFR and myosin II inhibitors cooperate to suppress EGFR-T790M-mutant NSCLC cells

Molecular Oncology

Volumn 6, Issue 3, 2012, Pages 299-310

  Chiu, Huan Chih ^a   Chang, Teng Yuan ^a   Huang, Chin Ting ^a   Chao, Yu Sheng ^a   Hsu, John T A ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; EGFR; MYH9; NSCLC; Target therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; BLEBBISTATIN; CYCLOOXYGENASE 2; CYTOSKELETON PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; METHIONINE; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 9; MYOSIN II INHIBITOR; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; THREONINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MUTANT; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; DRUG POTENTIATION; FLOW CYTOMETRY; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION;

EID: 84862780685     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.02.001     Document Type: Article

References (39)

1. Berg J.S., Powell B.C., Cheney R.E. A millennial myosin census. Mol. Biol. Cell. 2001, 12:780-794.
2. Bitler B.G., Goverdhan A., Schroeder J.A. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J. Cell. Sci. 2010, 123:1716-1723.
3. Chou T.C., Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 1983, 4:450-454.
4. de Lanerolle P., Johnson T., Hofmann W.A. Actin and myosin I in the nucleus: what next?. Nat. Struct. Mol. Biol. 2005, 12:742-746.
5. den Hartigh J.C., van Bergen en Henegouwen P.M., Verkleij A.J., Boonstra J. The EGF receptor is an actin-binding protein. J. Cell Biol. 1992, 119:349-355.
6. Discafani C.M., Carroll M.L., Floyd M.B., Hollander I.J., Husain Z., Johnson B.D., Kitchen D., May M.K., Malo M.S., Minnick A.A., Nilakantan R., Shen R., Wang Y.F., Wissner A., Greenberger L.M. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem. Pharmacol. 1999, 57:917-925.
7. Godin-Heymann N., Bryant I., Rivera M.N., Ulkus L., Bell D.W., Riese D.J., Settleman J., Haber D.A. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 2007, 67:7319-7326.
8. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
9. Grummt I. Actin and myosin as transcription factors. Curr. Opin. Genet. Dev. 2006, 16:191-196.
10. Hanada N., Lo H.W., Day C.P., Pan Y., Nakajima Y., Hung M.C. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol. Carcinog 2006, 45:10-17.
11. Hodge T., Cope M.J. A myosin family tree. J. Cell. Sci. 2000, 113:3353-3354.
12. Hofmann W.A., Stojiljkovic L., Fuchsova B., Vargas G.M., Mavrommatis E., Philimonenko V., Kysela K., Goodrich J.A., Lessard J.L., Hope T.J., Hozak P., de Lanerolle P. Actin is part of pre-initiation complexes and is necessary for transcription by RNA polymerase II. Nat. Cell Biol. 2004, 6:1094-1101.
13. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352:786-792.
14. Kobayashi S., Ji H., Yuza Y., Meyerson M., Wong K.K., Tenen D.G., Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005, 65:7096-7101.
15. Kobayashi S., Shimamura T., Monti S., Steidl U., Hetherington C.J., Lowell A.M., Golub T., Meyerson M., Tenen D.G., Shapiro G.I., Halmos B. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006, 66:11389-11398.
16. Kovacs M., Toth J., Hetenyi C., Malnasi-Csizmadia A., Sellers J.R. Mechanism of blebbistatin inhibition of myosin II. J. Biol. Chem. 2004, 279:35557-35563.
17. Li C., Iida M., Dunn E.F., Ghia A.J., Wheeler D.L. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009, 28:3801-3813.
18. Li Q., Sarna S.K. Nuclear myosin II regulates the assembly of preinitiation complex for ICAM-1 gene transcription. Gastroenterology 2009, 137:1051-1060.
19. Liccardi G., Hartley J.A., Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 2011, 71:1103-1114.
20. Limouze J., Straight A.F., Mitchison T., Sellers J.R. Specificity of blebbistatin, an inhibitor of myosin II. J. Muscle Res. Cell Motil. 2004, 25:337-341.
21. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3:802-808.
22. Lo H.W., Hsu S.C., Ali-Seyed M., Gunduz M., Xia W., Wei Y., Bartholomeusz G., Shih J.Y., Hung M.C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7:575-589.
23. Lo H.W., Xia W., Wei Y., Ali-Seyed M., Huang S.F., Hung M.C. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005, 65:338-348.
24. Lo H.W., Ali-Seyed M., Wu Y., Bartholomeusz G., Hsu S.C., Hung M.C. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importing beta1 and CRM1. J. Cell Biochem. 2006, 98:1570-1583.
25. Lo H.W. Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov. Med. 2010, 10:44-51.
26. Lo H.W., Cao X., Zhu H., Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol. Cancer Res. 2010, 8:232-245.
27. Nam D.H., Park K., Park C., Im Y.H., Kim M.H., Lee S., Hong S.C., Shin H.J., Kim J.H., Eoh W., McDonnell T.J. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol. Rep. 2004, 11:263-268.
28. Nguyen E., Besombes D., Debey P. Immunofluorescent localization of actin in relation to transcription sites in mouse pronuclei. Mol. Reprod. Dev. 1998, 50:263-272.
29. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:225-235.
30. Pazdrak K., Shi X.Z., Sarna S.K. TNFalpha suppresses human colonic circular smooth muscle cell contractility by SP1- and NF-kappaB-mediated induction of ICAM-1. Gastroenterology 2004, 127:1096-1109.
31. Pestic-Dragovich L., Stojiljkovic L., Philimonenko A.A., Nowak G., Ke Y., Settlage R.E., Shabanowitz J., Hunt D.F., Hozak P., de Lanerolle P. A myosin I isoform in the nucleus. Science 2000, 290:337-341.
32. Pujol A., Mosca R., Farres J., Aloy P. Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol. Sci. 2010, 31:115-123.
33. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
34. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., Gazdar A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97:339-346.
35. Smith S.S., Kelly K.H., Jockusch B.M. Actin co-purifies with RNA polymerase II. Biochem. Biophys. Res. Commun. 1979, 86:161-166.
36. Song W., Wu J., Ge G., Lin Q. Two domains of the epidermal growth factor receptor are involved in cytoskeletal interactions. Biochem. Biophys. Res. Commun. 2008, 370:589-593.
37. Straight A.F., Cheung A., Limouze J., Chen I., Westwood N.J., Sellers J.R., Mitchison T.J. Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor. Science 2003, 299:1743-1747.
38. Wang S.C., Hung M.C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin. Cancer Res. 2009, 15:6484-6489.
39. Xia W., Wei Y., Du Y., Liu J., Chang B., Yu Y.L., Huo L.F., Miller S., Hung M.C. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol. Carcinog 2009, 48:610-617.